Todd S. Crocenzi - Concepedia

Author

Todd S. Crocenzi

Providence Portland Medical Center ORCID

Also Known As

Crocenzi, Todd, T. Crocenzi, T. S. Crocenzi, T.S. Crocenzi, Todd Crocenzi, Todd S Crocenzi, Todd S. Crocenzi

Publications

25.8K

Citations

H-Index

Concepts

All Affiliations

Providence Portland Medical Center Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Clinica Universidad de Navarra Bristol-Myers Squibb (United States)

About

Todd S. Crocenzi is an author at Providence Portland Medical Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	26	12.2K
2	Hepatology	10	11	4.8K
3	Health Sciences	8	8	4.7K
4	Cell Biology	2	2	48
5	Clinical Immunology	1	1	10

Todd S. Crocenzi

Publications

24.8K

Citations

H-Index

Page 1

	Year	Citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Dung T. Le, Jennifer N. Uram, Hao Wang, New England Journal of Medicine	2015	9.2K
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Dung T. Le, Jennifer N. Durham, Kellie N. Smith, Science Solid TumorsPd-1 BlockadeImmunologyPathologyMismatch Repair Deficiency	2017	6.4K
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, The Lancet HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma	2017	4.2K
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Dung T. Le, Tae Won Kim, Eric Van Cutsem, Journal of Clinical Oncology	2019	975
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Journal of Clinical Oncology	2015	588
PD-1 blockade in tumors with mismatch repair deficiency. Dung T. Le, Jennifer N. Uram, Hao Wang, Journal of Clinical Oncology Tumor BiologyTumoral PathologyMalignant DiseasePd-1 BlockadeMedicine	2015	553
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients Brendan D. Curti, Magdalena Kovacsovics-Bankowski, Nicholas P. Morris, Cancer Research	2013	502
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking Andrew J. Gunderson, Tomoko Yamazaki, Kayla McCarty, Nature Communications	2020	204
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi, Journal of Clinical Oncology Antitumor ActivityImmunologyPharmacotherapyImmunotherapeuticsImmunotherapy	2015	196

Page 1